


CP-346086 dihydrate

| | |
|--------------------|---|
| Cat. No.: | HY-113955A |
| CAS No.: | 1262769-98-1 |
| Molecular Formula: | C ₂₆ H ₂₆ F ₃ N ₅ O ₃ |
| Molecular Weight: | 513.51 |
| Target: | Others |
| Pathway: | Others |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | | | | | | | | | |
|-------------------------------------|--|---------------|------------------------------|---------|-------------------------|-----------------|------------------------------------|---------|---|
| Description | CP-346086 dihydrate is a potent and orally active microsomal triglyceride transfer protein (MTP) inhibitor, with an IC ₅₀ of 2.0 nM for human and rodent MTP. CP-346086 dihydrate can lower plasma cholesterol and triglycerides in vivo ^[1] . | | | | | | | | |
| IC₅₀ & Target | IC ₅₀ : 2.0 nM (MTP) ^[1] | | | | | | | | |
| In Vitro | <p>CP-346086 (0.1-1000 nM) dose-dependently inhibits human MTP-mediated triglyceride transfer between vesicles with an IC₅₀ of 2.0 nM^[1].</p> <p>CP-346086 (24 h) inhibits apolipoprotein B (apoB) and triglyceride secretion (IC₅₀=2.6 nM) from Hep-G2 cells without affecting apoA-I secretion or lipid synthesis^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> | | | | | | | | |
| In Vivo | <p>CP-346086 (1-100 mg/kg; oral gavage once daily for 2 weeks) reduces plasma total, VLDL, and LDL cholesterol and triglycerides in mice^[1].</p> <p>CP-346086 (25 mg/kg; a single p.o.) results in an almost complete inhibition of Tyloxapol-induced triglyceride accumulation in fasted rats^[1].</p> <p>CP-346086 (0.1-10 mg/kg; a single p.o.) reduces acute plasma triglyceride in mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>B6CBAF1J mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>1, 2, 10, 20, 100 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral gavage once daily for 2 weeks</td> </tr> <tr> <td>Result:</td> <td>Lowered total, VLDL, and LDL cholesterol and triglycerides dose dependently with 23%, 33%, 75%, and 62% reductions at 10 mg/kg/day.</td> </tr> </table> | Animal Model: | B6CBAF1J mice ^[1] | Dosage: | 1, 2, 10, 20, 100 mg/kg | Administration: | Oral gavage once daily for 2 weeks | Result: | Lowered total, VLDL, and LDL cholesterol and triglycerides dose dependently with 23%, 33%, 75%, and 62% reductions at 10 mg/kg/day. |
| Animal Model: | B6CBAF1J mice ^[1] | | | | | | | | |
| Dosage: | 1, 2, 10, 20, 100 mg/kg | | | | | | | | |
| Administration: | Oral gavage once daily for 2 weeks | | | | | | | | |
| Result: | Lowered total, VLDL, and LDL cholesterol and triglycerides dose dependently with 23%, 33%, 75%, and 62% reductions at 10 mg/kg/day. | | | | | | | | |

REFERENCES

[1]. Chandler CE, et, al. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res. 2003 Oct;44(10):1887-901.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA